Exam NAPLEX Topic 3 Question 96 Discussion

Actual exam question for NABP's NAPLEX exam
Question #: 96
Topic #: 3
Which of the following beta-blocker is NOT proven to reduce mortality in patients with Systolic CHF?

Suggested Answer: E Vote an answer

Nadolol is not proven to reduce mortality in patients with systolic CHF. The efficacy of nadolol in HF has not been determined. For patients taking nadolol, it should be used with caution in those with compensated heart failure and patients should be monitored for a worsening of the condition. Bisoprolol, carvedilol, and sustained- release metoprolol succinate are the beta-blockers that have been proven to reduce mortality in patients with systolic CHF. These 3 beta-blockers have been effective in reducing the risk of death in patients with chronic HFrEF. Other beta-blockers were found to be less effective. Bucindolol did not exhibit uniform effectiveness across different populations. Metoprolol tartrate was found to be less effective in HF clinical trials.
Reference:
http://circ.ahajournals.org/content/128/16/e240

by Elijah at Mar 12, 2026, 06:07 AM

Limited Time Offer

15%

Off

Get Premium NAPLEX Questions as Interactive Self Test Engine or PDF

Comments

Chosen Answer:
This is a voting comment (?) , you can switch to a simple comment.
Switch to a voting comment New
Nick name: Submit Cancel
A voting comment increases the vote count for the chosen answer by one.

Upvoting a comment with a selected answer will also increase the vote count towards that answer by one. So if you see a comment that you already agree with, you can upvote it instead of posting a new comment.
0
0
0
10